| Product Code: ETC10186450 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Japan Primary Progressive Multiple Sclerosis Market Overview |
3.1 Japan Country Macro Economic Indicators |
3.2 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, 2021 & 2031F |
3.3 Japan Primary Progressive Multiple Sclerosis Market - Industry Life Cycle |
3.4 Japan Primary Progressive Multiple Sclerosis Market - Porter's Five Forces |
3.5 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Japan Primary Progressive Multiple Sclerosis Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about primary progressive multiple sclerosis (PPMS) in Japan |
4.2.2 Growth in research and development activities for new treatment options |
4.2.3 Rising prevalence of multiple sclerosis cases in Japan |
4.3 Market Restraints |
4.3.1 High cost of PPMS treatments leading to affordability issues for patients |
4.3.2 Limited availability of approved therapies for PPMS in Japan |
5 Japan Primary Progressive Multiple Sclerosis Market Trends |
6 Japan Primary Progressive Multiple Sclerosis Market, By Types |
6.1 Japan Primary Progressive Multiple Sclerosis Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Drug Class, 2021 - 2031F |
6.1.3 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.1.4 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Immunosuppressants, 2021 - 2031F |
6.1.5 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Corticosteroids, 2021 - 2031F |
6.1.6 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Others, 2021 - 2031F |
6.2 Japan Primary Progressive Multiple Sclerosis Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Disease-Modifying Therapy, 2021 - 2031F |
6.2.3 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Physical Therapy, 2021 - 2031F |
6.2.4 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Rehabilitation, 2021 - 2031F |
6.2.5 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Others, 2021 - 2031F |
6.3 Japan Primary Progressive Multiple Sclerosis Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.3.3 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Oral, 2021 - 2031F |
6.3.4 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Injection, 2021 - 2031F |
6.3.5 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Others, 2021 - 2031F |
6.4 Japan Primary Progressive Multiple Sclerosis Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Specialty Clinics, 2021 - 2031F |
6.4.4 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.4.5 Japan Primary Progressive Multiple Sclerosis Market Revenues & Volume, By Others, 2021 - 2031F |
7 Japan Primary Progressive Multiple Sclerosis Market Import-Export Trade Statistics |
7.1 Japan Primary Progressive Multiple Sclerosis Market Export to Major Countries |
7.2 Japan Primary Progressive Multiple Sclerosis Market Imports from Major Countries |
8 Japan Primary Progressive Multiple Sclerosis Market Key Performance Indicators |
8.1 Average time from diagnosis to treatment initiation for PPMS patients in Japan |
8.2 Number of clinical trials focused on PPMS treatments in Japan |
8.3 Patient adherence rate to PPMS treatment plans |
8.4 Number of healthcare providers specializing in PPMS care |
8.5 Percentage of PPMS patients receiving timely access to healthcare services |
9 Japan Primary Progressive Multiple Sclerosis Market - Opportunity Assessment |
9.1 Japan Primary Progressive Multiple Sclerosis Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Japan Primary Progressive Multiple Sclerosis Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 Japan Primary Progressive Multiple Sclerosis Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Japan Primary Progressive Multiple Sclerosis Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Japan Primary Progressive Multiple Sclerosis Market - Competitive Landscape |
10.1 Japan Primary Progressive Multiple Sclerosis Market Revenue Share, By Companies, 2024 |
10.2 Japan Primary Progressive Multiple Sclerosis Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here